Citadel Advisors
CYT

Citadel Advisors’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Citadel Advisors’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-21,044
Closed -$34.7K – 15801
2022
Q4 		$34.7K Buy
+21,044
New +$33.8K ﹤0.01% 12581
2022
Q2 		– Sell
-42,746
Closed -$162K – 14457
2022
Q1 		$162K Buy
+42,746
New +$243K ﹤0.01% 11774
2021
Q4 		– Sell
-27,510
Closed -$482K – 15045
2021
Q3 		$482K Buy
+27,510
New +$514K ﹤0.01% 9961

Other funds holding CYT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Aldebaran Capital Carmel, Indiana $131M AUM 34.7% 1-Year Est. Return

Citadel Advisors's CYT Position: Q1 2023 in Review

Citadel Advisors sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q1 2023, closing a stake of 21,044 shares — an estimated $34.7K sold.

Citadel Advisors first reported a position in CYT in Q3 2021 and held it in 3 quarters. The position peaked at $482K in Q3 2021. 32 funds tracked by Wall St. Rank hold CYT as of Q1 2023.

  • Citadel Advisors reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Citadel Advisors sold 21,044 Cyteir Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $34.7K.
  • Citadel Advisors first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q3 2021 and held it in 3 quarters.
  • Citadel Advisors's Cyteir Therapeutics, Inc. Common Stock position peaked at $482K in Q3 2021.
  • 32 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.